Healthcare resource utilisation (HRU) in the Asthma Salford Lung Study (SLS asthma)

SLS asthma demonstrated the effectiveness and safety of initiating once-daily inhaled fluticasone furoate/vilanterol (FF/VI) 100[200]/25µg vs continuing usual care (UC) in patients (pts) with symptomatic asthma in UK primary care.1 Here, we describe HRU and costs in SLS asthma.HRU data were captured remotely in real-time via pts’ electronic health records using a primary/secondary care-linked database system. Prespecified HRU and cost analyses were conducted in the intent-to-treat population.At baseline: mean age 50 yrs, 74% asthma duration ≥10 yrs, 38% current comorbidities, 90%/50% day/nighttime symptoms. All-cause primary care contact (PCC) rates were slightly but significantly higher for FF/VI vs UC, with no differences in all-cause secondary care contact (SCC) or asthma-related PCC/SCC rates (Table). Most PCC/SCC were non-asthma-related. Hospitalisation rates were significantly higher for FF/VI vs UC. Total asthma medical costs were driven largely by study drug costs and were significantly lower for FF/VI vs UC.Higher rates of all-cause vs asthma-related PCC/SCC in SLS asthma highlight the burden of non-asthma-related disease in routine care; this aligns with findings in SLS COPD,2 despite a younger, less comorbid population. Higher all-cause PCC rates for FF/VI vs UC may reflect the pre-licence status of FF/VI at study start. Initiating FF/VI may be less costly than continuing with UC.Funding: GSK (HZA115150/NCT01706198)

Source: European Respiratory Journal - November 19, 2018 Category: Respiratory Medicine Authors: Browning, D., Diar Bakerly, N., New, J. P., Stein, N., Svedsater, H., Leather, D. A., Lay-Flurrie, J., Fletcher, J. Tags: Monitoring Airway Disease Source Type: research